Edward J. Dulac, III net worth and biography

Edward Dulac, III Biography and Net Worth

CFO of Fate Therapeutics

Edward Dulac is Chief Financial Officer at Fate Therapeutics. Prior to joining Fate, Mr. Dulac served as Vice President of Business Development & Strategy at Celgene, where he was responsible for business development opportunities in the therapeutic areas of hematology and oncology, inflammation and immunology, and neuroscience. During his tenure at Celgene, he also held various positions of increasing responsibility in the company’s hematology and oncology franchise, including portfolio development strategy and commercial planning. Prior to Celgene, Mr. Dulac worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers and in corporate finance at Pfizer. Mr. Dulac received a B.S. in Pharmacy from the University of Pittsburgh and an M.B.A. from the Kelley School of Business at Indiana University.

What is Edward J. Dulac, III's net worth?: The estimated net worth of Edward J. Dulac, III is at least $195,380.88 as of January 29th, 2024. Mr. Dulac, III owns 103,926 shares of Fate Therapeutics stock worth more than $195,381 as of December 18th. This net worth estimate does not reflect any other assets that Mr. Dulac, III may own. Learn More about Edward J. Dulac, III's net worth.
How do I contact Edward J. Dulac, III?: The corporate mailing address for Mr. Dulac, III and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]. Learn More on Edward J. Dulac, III's contact information.
Has Edward J. Dulac, III been buying or selling shares of Fate Therapeutics?: Edward J. Dulac, III has not been actively trading shares of Fate Therapeutics over the course of the past ninety days. Most recently, Edward J. Dulac III sold 1,849 shares of the business's stock in a transaction on Monday, January 29th. The shares were sold at an average price of $5.00, for a transaction totalling $9,245.00. Following the completion of the sale, the chief financial officer now directly owns 103,926 shares of the company's stock, valued at $519,630. Learn More on Edward J. Dulac, III's trading history.
Who are Fate Therapeutics' active insiders?: Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.
Are insiders buying or selling shares of Fate Therapeutics?: In the last year, Fate Therapeutics insiders bought shares 1 times. They purchased a total of 44,630 shares worth more than $166,023.60. In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 46,046 shares worth more than $202,409.98. The most recent insider tranaction occured on August, 6th when Director Yuan Xu sold 633 shares worth more than $2,677.59. Insiders at Fate Therapeutics own 5.0% of the company. Learn More about insider trades at Fate Therapeutics.
Information on this page was last updated on 8/6/2024.

Edward J. Dulac, III Insider Trading History at Fate Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/29/2024	Sell	1,849	$5.00	$9,245.00	103,926
1/9/2024	Sell	7,028	$4.37	$30,712.36	105,775
8/18/2023	Sell	4,718	$2.80	$13,210.40	119,570
7/5/2023	Sell	5,182	$4.83	$25,029.06	124,288
1/10/2023	Sell	7,331	$5.24	$38,414.44	129,470
8/18/2022	Sell	5,135	$29.81	$153,074.35	136,801
1/11/2022	Sell	1,770	$48.45	$85,756.50
12/20/2021	Sell	15,977	$60.00	$958,620.00
9/28/2021	Sell	19,460	$62.53	$1,216,833.80
8/19/2021	Sell	3,474	$88.26	$306,615.24	56,076

Edward J. Dulac, III Buying and Selling Activity at Fate Therapeutics

Fate Therapeutics Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $1.88

$1.85

$2.02

50 Day Range

MA: $2.63

$1.83

$3.23

2 Week Range

Now: $1.88

$1.82

$8.83

Volume

2,811,176 shs

Average Volume

2,407,703 shs

Market Capitalization

$214.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.